NCT04808245 — German Cancer Research Center cancer vaccine trial
A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas
Registry record
| Registry ID | NCT04808245 ↗ |
|---|---|
| Lead sponsor | German Cancer Research Center |
| Collaborators | Johannes Gutenberg University Mainz, Charite University, Berlin, Germany, Roche Pharma AG, German Cancer Aid |
| Phase | Phase 1 |
| Status | Active Not Recruiting |
| Indication | Newly Diagnosed H3-mutated Glioma |
| Enrollment | 15 participants (target) |
| Start date | 2023-02-15 |
| Primary completion | 2026-11 (est.) |
| Last registry update | 15 Sept 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT04808245), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT04808245?
NCT04808245 (A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas) is registered on ClinicalTrials.gov as Phase 1, sponsored by German Cancer Research Center.
Is NCT04808245 recruiting?
As of the 2026-09-15 registry update, NCT04808245 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT04808245?
The lead sponsor is German Cancer Research Center. Collaborators: Johannes Gutenberg University Mainz, Charite University, Berlin, Germany, Roche Pharma AG, German Cancer Aid.
What condition does NCT04808245 study?
The registered condition is Newly Diagnosed H3-mutated Glioma. Primary completion is listed as 2026-11 (estimated).
Are results available for NCT04808245?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT04808245.
Back to the full neoantigen vaccine trial tracker — 106 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.